Literature DB >> 25848475

Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system?

Xavier Adhoute1, Guillaume Penaranda1, Paul Castellani1, Herve Perrier1, Marc Bourliere1.   

Abstract

Several hepatocellular carcinoma (HCC) staging systems have been established, and a variety of country-specific treatment strategies are also proposed. The barcelona - clinic liver cancer (BCLC) system is the most widely used in Europe. The Hong Kong liver Cancer is a new prognostic staging system; it might become the reference system in Asia. Transarterial chemoembolization (TACE) is the most widely used treatment for HCC worldwide; but it showed a benefit only for intermediate stage HCC (BCLC B), and there is still no consensus concerning treatment methods and treatment strategies. In view of the highly diverse nature of HCC and practices, a scoring system designed to assist with decision making before the first TACE is performed or prior to repeating the procedure would be highly useful.

Entities:  

Keywords:  Barcelona Clinic Liver Cancer; Hepatocellular carcinoma; Prognostic scoring systems; Transarterial chemoembolization

Year:  2015        PMID: 25848475      PMCID: PMC4381174          DOI: 10.4254/wjh.v7.i3.521

Source DB:  PubMed          Journal:  World J Hepatol


  51 in total

Review 1.  Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

Authors:  J-L Raoul; B Sangro; A Forner; V Mazzaferro; F Piscaglia; L Bolondi; R Lencioni
Journal:  Cancer Treat Rev       Date:  2010-08-17       Impact factor: 12.111

2.  A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization.

Authors:  L Lladó; J Virgili; J Figueras; C Valls; J Dominguez; A Rafecas; J Torras; J Fabregat; J Guardiola; E Jaurrieta
Journal:  Cancer       Date:  2000-01-01       Impact factor: 6.860

3.  Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia.

Authors:  Kwang-Hyub Han; Masatochi Kudo; Sheng-Long Ye; Jong Young Choi; Roonni Tung-Ping Poon; Jinsil Seong; Joong-Won Park; Takafumi Ichida; Jin Wook Chung; Pierce Chow; Ann-Lii Cheng
Journal:  Oncology       Date:  2011-12-22       Impact factor: 2.935

Review 4.  Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma.

Authors:  Roberto S Oliveri; Jørn Wetterslev; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

5.  Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial.

Authors:  Masatoshi Akamatsu; Haruhiko Yoshida; Shuntaro Obi; Shinpei Sato; Yukihiro Koike; Tomonori Fujishima; Ryosuke Tateishi; Masatoshi Imamura; Keisuke Hamamura; Takuma Teratani; Shuichiro Shiina; Takashi Ishikawa; Masao Omata
Journal:  Liver Int       Date:  2004-12       Impact factor: 5.828

Review 6.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

Review 7.  Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

Authors:  Calogero Cammà; Filippo Schepis; Ambrogio Orlando; Maddalena Albanese; Lillian Shahied; Franco Trevisani; Pietro Andreone; Antonio Craxì; Mario Cottone
Journal:  Radiology       Date:  2002-07       Impact factor: 11.105

8.  Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization.

Authors:  J W Chung; J H Park; J K Han; B I Choi; M C Han; H S Lee; C Y Kim
Journal:  Radiology       Date:  1996-01       Impact factor: 11.105

9.  Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?

Authors:  Alejandro Forner; Carmen Ayuso; María Varela; Jordi Rimola; Amelia J Hessheimer; Carlos Rodriguez de Lope; María Reig; Luís Bianchi; Josep M Llovet; Jordi Bruix
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

10.  Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.

Authors:  Johannes Lammer; Katarina Malagari; Thomas Vogl; Frank Pilleul; Alban Denys; Anthony Watkinson; Michael Pitton; Geraldine Sergent; Thomas Pfammatter; Sylvain Terraz; Yves Benhamou; Yves Avajon; Thomas Gruenberger; Maria Pomoni; Herbert Langenberger; Marcus Schuchmann; Jerome Dumortier; Christian Mueller; Patrick Chevallier; Riccardo Lencioni
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11-12       Impact factor: 2.740

View more
  6 in total

Review 1.  Usefulness of staging systems and prognostic scores for hepatocellular carcinoma treatments.

Authors:  Xavier Adhoute; Guillaume Penaranda; Jean Luc Raoul; Patrice Le Treut; Emilie Bollon; Jean Hardwigsen; Paul Castellani; Hervé Perrier; Marc Bourlière
Journal:  World J Hepatol       Date:  2016-06-18

2.  Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion.

Authors:  Imam Waked; Sarah Berhane; Hidenori Toyoda; Stephen L Chan; Nicholas Stern; Daniel Palmer; Toshifumi Tada; Winnie Yeo; Frankie Mo; Dominik Bettinger; Martha M Kirstein; Mercedes Iñarrairaegui; Asmaa Gomaa; Arndt Vogel; Tim Meyer; Bruno Sangro; Paul Lai; Takashi Kumada; Philip J Johnson
Journal:  Br J Cancer       Date:  2017-01-26       Impact factor: 7.640

3.  Study to evaluate the immunomodulatory effects of radiofrequency ablation compared to surgical resection for liver cancer.

Authors:  Ketevan Mazmishvili; Kumar Jayant; Nona Janikashvili; Nino Kikodze; Malkhaz Mizandari; Ia Pantsulaia; Natela Paksashvili; Mikael H Sodergren; Isabella Reccia; Madhava Pai; Nagy Habib; Tinatin Chikovani
Journal:  J Cancer       Date:  2018-08-06       Impact factor: 4.207

4.  "Six-and-twelve" score for outcome prediction of hepatocellular carcinoma following transarterial chemoembolization. In-depth analysis from a multicenter French cohort.

Authors:  Xavier Adhoute; Guillaume Pénaranda; Jean-Luc Raoul; Jean-Pierre Bronowicki; Rodolphe Anty; Marc Bourlière
Journal:  World J Hepatol       Date:  2020-08-27

5.  A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function.

Authors:  Joon Yeul Nam; A Reum Choe; Dong Hyun Sinn; Jeong-Hoon Lee; Hwi Young Kim; Su Jong Yu; Yoon Jun Kim; Jung-Hwan Yoon; Jeong Min Lee; Jin Wook Chung; Sun Young Choi; Jeong Kyong Lee; Seung Yon Baek; Hye Ah Lee; Tae Hun Kim; Kwon Yoo
Journal:  BMC Cancer       Date:  2020-06-01       Impact factor: 4.430

6.  The Effectiveness of ART Score in Selecting Patients for Transarterial Chemoembolization Retreatment: A Cohort Study in Taiwan.

Authors:  Chi-Lung Tseng; Wei-Jen Lai; Chun-Jui Huang; Yi-Hsiang Huang; Chien-Wei Su; I-Cheng Lee; Hsiou-Shan Tseng; Chung-Pin Li; Rheun-Chuan Lee; Han-Chieh Lin; Yee Chao
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.